Citations

Clear

415 citation(s) found for "Black, DF".

Abstract C038: Science of Cancer Survivorship Advocacy: Perspectives from Black Prostate Cancer Survivors
Fullwood, Dottington , Young, Mary Ellen

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: C038-C038

10.1158/1538-7755.disp24-c038 Get It

Abstract Background: Prostate cancer remains a significant health concern, particularly among Black men who experience higher incidence rates and poorer outcomes compared to other racial and ethnic groups. Despite advances in survivorship care, disparities persist in the survivorship experiences, underlying the urgent need for research focusing on the unique needs of Black men in prostate cancer survivorship. By understanding the advocacy efforts and experiences of Black men who have completed prostate cancer treatment, we can identify strategies to better support this vulnerable population and inform interventions aimed at improving survivorship outcomes. Our study explored the advocacy efforts, experiences, and skills of Black men post-prostate cancer treatment to inform targeted interventions aimed at improving survivorship outcomes. Methods: Qualitative interviews were used to obtain information from 31 Black prostate cancer survivors who have completed treatment to explore their insights on survivorship and advocacy. Grounded Theory approach was utilized to analyze participants’ narratives. We employed open and axial coding techniques to extract themes from audio-recorded interviews that were then transcribed, verified and deidentified. Results: We identified several significant themes among Black men who completed prostate cancer treatment. First, participants actively engaged in "spreading the word," advocating for awareness and early detection within their communities through various channels. Second, they emphasized "the importance of advocacy," advocating for themselves and policy changes to address healthcare disparities. Third, participants were committed to "sharing information," openly discussing experiences and providing support to others navigating prostate cancer. Additionally, they highlighted the significance of "reflecting back," drawing from their life stories to offer valuable insights and guidance. Conclusion: This study sheds light on the advocacy efforts and experiences of Black men who have completed prostate cancer treatment, offering valuable insights into their perspectives and actions within their communities. Through the identification of five significant themes, including spreading awareness, advocacy importance, information sharing, and reflective support, this research underscores the proactive engagement of participants in addressing the challenges of prostate cancer. By amplifying the voices and experiences of these individuals, this study contributes to a deeper understanding of the multifaceted nature of prostate cancer survivorship within marginalized communities, ultimately informing future interventions and policies aimed at improving outcomes and reducing disparities in prostate cancer survivorship care. Citation Format: Fullwood, Mary Ellen Young, Folakemi T. Odedina. Science of Cancer Survivorship Advocacy: Perspectives from Black Prostate Cancer Survivors [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C038.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary, Nadine J. , Merle, James L. , Richardson, Joshua E. , Garcia, Sofia F. , Tesch, Nathan , DiMartino, Lisa , Hassett, Michael J. , Cella, David , Smith, Justin D. , Kroner, Barbara L, Ruddy, Kathryn, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Cahue, September, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Faris, Nicolas, Flores, Anne Marie, Garcia, Martha, Hodgdon, Christine, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearson, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Richardson, Kimberly, Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tramontano, Angela C. , Wong, Sandra , Cella, David , Garcia, Sofia F , Bass, Michael , Cheville, Andrea , Mitchell, Sandra A , Jensen, Roxanne E. , Minteer, Sarah A. , Austin, Jessica D. , Osarogiagbon, Raymond U. , Wong, Sandra L. , Schrag, Deborah , Smith, Ashley Wilder , Kroner, Barbara L, Griffin, Joan M. , Ruddy, Kathryn J. , Ardini, Mary-Anne , Barrett, Fiona, Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Popovic, Jennifer R. , Preiss, Liliana , Reich, James, Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JAMIA Open | September 5, 2024 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooae081 | PMID 39234146 Get It

AbstractObjectivesTo report lessons from integrating the methods and perspectives of clinical informatics (CI) and implementation science (IS) in the context of Improving the Management of symPtoms during and following Cancer Treatment (IMPACT) Consortium pragmatic trials.Materials and MethodsIMPACT informaticists, trialists, and implementation scientists met to identify challenges and solutions by examining robust case examples from 3 Research Centers that are deploying systematic symptom assessment and management interventions via electronic health records (EHRs). Investigators discussed data collection and CI challenges, implementation strategies, and lessons learned.ResultsCI implementation strategies and EHRs systems were utilized to collect and act upon symptoms and impairments in functioning via electronic patient-reported outcomes (ePRO) captured in ambulatory oncology settings. Limited EHR functionality and data collection capabilities constrained the ability to address IS questions. Collecting ePRO data required significant planning and organizational champions adept at navigating ambiguity.DiscussionBringing together CI and IS perspectives offers critical opportunities for monitoring and managing cancer symptoms via ePROs. Discussions between CI and IS researchers identified and addressed gaps between applied informatics implementation and theory-based IS trial and evaluation methods. The use of common terminology may foster shared mental models between CI and IS communities to enhance EHR design to more effectively facilitate ePRO implementation and clinical responses.ConclusionImplementation of ePROs in ambulatory oncology clinics benefits from common understanding of the concepts, lexicon, and incentives between CI implementers and IS researchers to facilitate and measure the results of implementation efforts.
Drinking the disease: A family affected by arsenic in well water
Jegen, Dominika , Grygleski, Megan

Mayo Clinic

Canadian Journal of Rural Medicine | August 19, 2024 | Volume: 29 | Issue: 3 | Pages: 132-134

10.4103/cjrm.cjrm_2_24 | PMID 39155636 Get It

Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al‐Karaghouli, Mustafa , Ventura‐Cots, Meritxell , Wong, Yu Jun , Genescà, Joan , Mathurin, Philippe, Shawcross, Debbie L. , Vargas, Vı́ctor , Verna, Elizabeth C. , Caballería, Joan, Shah, Vijay J., Kamath, Patrick S. , Lucey, Michael R. , García‐Tsao, Guadalupe , Mathurin, Philippe , Shawcross, Debbie Lindsay , Vargas, Victor , Ventura Cots, Meritxell , Bosques, Francisco , Brown, Robert S. , Louvet, Alexandre , Schnabl, Bernd , García–Tsao, Guadalupe , Bataller, Ramon A , Abraldeṣ, Juan G.

Mayo Clinic

Hepatology Communications | July 31, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000495 | PMID 39082963 Get It

Background:Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium.Methods:Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs.Results:Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14–1.27) (p< 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12–1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention.Conclusion:We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials.
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement
Thota, Ramya , Hurley, Patricia A. , Miller, Therica M. , Bruinooge, Suanna S. , Lipset, Craig , Harvey, R. Donald , Black, Lora , Dinsdale, Amanda , Merrill, Janette K. , Pollastro, Teri , Prindiville, Sheila A. , Rizvi, Mujahid A., Sherwood, Shimere , Nowakowski, Grzegorz S. , Black, Lora J , Harvey, R Donald , Hurley, Patricia , Bruinooge, Suanna Steeby

Mayo Clinic

Journal of Clinical Oncology | July 30, 2024 | Volume: 42 | Issue: 33 | Pages: 3986-3995

10.1200/jco.24.00961 | PMID 39079075 Get It

Strategies to bring clinical trials closer to patients gained momentum during the COVID-19 pandemic, enabling more participants to receive treatment and/or testing in their local communities. Incorporation of decentralized trial elements presents both opportunities and challenges, spanning regulatory, technical, and operational aspects. This ASCO research statement includes timely consensus-driven recommendations and a call for engagement of all research stakeholders. ASCO held multistakeholder meetings with leaders in oncology research and concluded that research-related regulatory and administrative requirements and burdens present critical barriers to decentralizing trials. One example is sponsor and contract research organization (CRO) use of US Food and Drug Administration (FDA)'s Statement of Investigator (Form 1572), which was found to exceed FDA's stated intent and used in conservative ways disproportionate to potential risks to participants and scientific integrity. As a result, research sites experience an avalanche of downstream administrative and regulatory activities that consume considerable resources. This statement recommends four key solutions to address such barriers and recalibrate regulatory and administrative expectations for decentralizing trials: (1) FDA should engage the research community in a public-private partnership to modernize standards and enable local access to trials; (2) sponsors and CROs should develop standards and protocols that accommodate flexible approaches, enable local participation, provide clarity around roles and requirements, and promote consistency; (3) research centers, networks, and sites should update policies and procedures to implement decentralized trial elements; and (4) research community should develop a streamlined, uniform mechanism to simplify regulatory data collection and documentation and use it consistently across trials. We can and must prioritize a concerted commitment to simplify and streamline regulatory requirements and practices to broaden access to and participation in cancer clinical trials.
Esophageal cancer mortality disparities between Black and White adults in the United States, 1999–2020: insights from CDC‐WONDER
Pan, Chun‐Wei , Wang, Yichen , Abboud, Yazan , Dominguez, Alejandro Nieto , Pang, Maoyin , Pang, Maoyin , Wang, Yichen , Lo, Chun‐Han

Mayo Clinic

Journal of Gastroenterology and Hepatology | July 24, 2024 | Volume: 39 | Issue: 11 | Pages: 2340-2350

10.1111/jgh.16689 | PMID 39048101 Get It

AbstractBackground and AimEsophageal cancer significantly contributes to US cancer mortality, with notable racial disparities. This study aims to provide updated esophageal cancer mortality trends among Black and White adults from 1999 to 2020.MethodsCDC‐WONDER was used to identify Black and White adults in the United States from 1999 to 2020. We calculated age‐standardized mortality rates, absolute rate differences, and rate ratios to compare the mortality differences between these populations.ResultsFrom 1999 to 2020 in the United States, there were 303 267 esophageal cancer deaths, with significant racial disparities. The age‐adjusted mortality rate for Black adults fell from 6.52 to 2.62 per 100 000, while for White adults, it declined from 4.19 to 3.97 per 100 000, narrowing the racial mortality gap. Gender‐wise, the study showed a decrease in the mortality rate from 3.31 to 2.29 per 100 000 in Black women, but an increase from 1.52 to 1.99 per 100 000 in White women. Among young men, the rate dropped in Black men from 12.82 to 6.26 per 100 000 but rose in White men from 9.90 to 10.57 per 100 000. Regionally, Black adults in the Midwest and South initially had higher mortality rates than Whites, but this gap reduced over time. By 2020, Black men had lower mortality rates across all regions.ConclusionsOver the last two decades, age‐adjusted esophageal cancer mortality decreased in Black adults but stabilized in White adults, reflecting distinct cancer trends and risk factors. The study highlights the importance of tailored public health strategies for healthcare access and risk factor management.
Comparison Between Black Non‐Hispanic and White Non‐Hispanic Simultaneous Pancreas‐Kidney Transplant Candidates and Recipients
Green, Shawna , Spaulding, Aaron , Brennan, Emily , Jarmi, Tambi , Green, Shawna M , Spaulding, Aaron , Vargas, Emily , Jarmi, Tambi

Mayo Clinic

Clinical Transplantation | July 5, 2024 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/ctr.15392 | PMID 38967601 Get It

ABSTRACTIntroductionThis study examined simultaneous pancreas–kidney transplant (SPKt) in Black and White patients to identify disparities in transplantation, days on the waitlist, and reasons for SPKt waitlist removal.MethodsUsing the United Network for Organ Sharing Standard Transplant Analysis and Research file, patients between January 1, 2009, and May 31, 2021, were included. Three cohorts (overall, SPKt recipients only, and those not transplanted) were selected using propensity score matching. Conditional logistic regression was used for categorical outcomes. Days on the waitlist were compared using negative binomial regression.ResultsBlack patients had increased odds of receiving a SPKt (OR, 1.25 [95% CI, 1.11–1.40], p < 0.001). White patients had increased odds of receiving a kidney‐only transplant (OR 0.48 [95% CI, 0.38–0.61], p < 0.001), and specifically increased odds of receiving a living donor kidney (OR 0.34 [0.25–0.45], p < 0.001).ConclusionThis study found that Black patients are more likely to receive a SPKt. Results suggest that there are opportunities for additional inquiry related to patient removal from the waitlist, particularly considering White patients received or accepted more kidney‐only transplants and were more likely to receive a living donor kidney‐only transplant.
Heart failure with preserved ejection fraction management: a systematic review of clinical practice guidelines and recommendations
Mahmood, Adil , Dhall, Eamon , Gallagher, Angela , Zakeri, Rosita , Mohammed, Selma F. , Ricci, Fabrizio , Aung, Nay , Khanji, Mohammed Y , Gallagher, Angela , Chahal, Anwar A, Ricci, Fabrizio , Aung, Nay , Khanji, Mohammed Yunus , Zakeri, Rosita , Primus, C , Chahal, C. Anwar A. , Ricci, Fabrizio

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | June 26, 2024 | Volume: 10 | Issue: 7 | Pages: 571-589

10.1093/ehjqcco/qcae053 | PMID 38918060 Get It

Abstract Multiple guidelines exist for the diagnosis and management of heart failure with preserved ejection fraction (HFpEF). We systematically reviewed current guidelines and recommendations, developed by national and international medical organizations, on the management of HFpEF in adults to aid clinical decision-making. We searched MEDLINE and EMBASE on 28 February 2024 for publications over the last 10 years as well as websites of organizations relevant to guideline development. Of the 10 guidelines and recommendations retrieved, 7 showed considerable rigour of development and were subsequently retained for analysis. There was consensus on the definition of HFpEF and the diagnostic role of serum natriuretic peptides and resting transthoracic echocardiography. Discrepancies were identified in the thresholds of serum natriuretic peptides and transthoracic echocardiography parameters used to diagnose HFpEF. There was agreement on the general pharmacological and supportive management of acute and chronic HFpEF. However, differences exist in strategies to identify and address specific phenotypes. Contemporary guidelines for HFpEF management agree on measures to avoid its development and the consideration of cardiac transplantation in advanced diseases. There were discrepancies in recommended frequency of surveillance for patients with HFpEF and sparse recommendations on screening for HFpEF in the general population, use of diagnostic scoring systems, and the role of newly emerging therapies.
The state of cancer-focused community outreach and engagement (COE): reflections of Black COE directors
Thompson, Hayley S. , Barrett, Nadine J. , Odedina, Folakemi T., Rhoads, Kim F. , Barrett, Nadine , Ashing, Kimlin , Baskin, Monica L. , Carter‐Harris, Lisa , Nolan, Timiya S. , Sheppard, Vanessa B. , Zeigler-Johnson, Charnita M

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 15, 2024 | Volume: 116 | Issue: 10 | Pages: 1549-1554

10.1093/jnci/djae138 | PMID 38876978 Get It

Abstract The requirement of community outreach and engagement (COE) as a major component of the National Cancer Institute (NCI) Cancer Center Support Grant has had an enormous impact on the way NCI-designated cancer centers identify, investigate, and address the needs of their catchment area (CA) communities. Given the wide-ranging diversity of our nation, COE’s scope of work (SOW) is extremely demanding and complex. Yet, COE is often marginalized and viewed as void of scientific methods when, in fact, it requires specialized scientific knowledge and a broad range of proficiencies. Black COE scientific directors may be particularly attuned to this marginalization as they have often confronted workplace inequities that resemble the health inequities observed within their cancer center’s CA. Thus, Black COE leaders are uniquely positioned to offer insight on the past, present, and future of COE. Key areas discussed include the low involvement of minoritized group members and those with appropriate expertise in national COE leadership; the lack of established, consistent criteria for evaluation of COE components and qualifications of evaluators; the need for substantial financial investment in COE; potential misalignment of community priorities and cancer center objectives; professional development and growth of COE staff and leaders; the expanding scope of COE across their respective cancer centers and CAs; and the need for center-wide involvement in COE and an “all-hands-on-deck” approach. These areas warrant thoughtful dialogue as COE evolves, for the benefit and success of all COE leaders. However, this dialogue must include diverse voices representing similarly diverse stakeholders at every level.
Black-White differences in ceramides, cardiovascular health, and cardiovascular risk: a comparative study of US observational cohorts
Lalika, M, Vasile, Vlad C. , Johnson, Matthew P. , Cooper, Lynn A., Lalika, Mathias , Hayes, Sharonne N. , Jones, Clarence , Cooper, L A, Patten, Christi A. , Brewer, LaPrincess C.

Mayo Clinic

European Journal of Preventive Cardiology | June 14, 2024 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwae175.291 Get It

Abstract Background Despite advances in cardiovascular (CV) care, African American adults experience worse CV disease (CVD) outcomes than White adults, warranting the investigation of CVD prediction biomarkers. Plasma ceramides are bioactive lipids that are biomarkers of adverse cardiovascular risk for both primary and secondary prevention. However, racial/ethnic differences in ceramide levels and their link to CV health (CVH) in African American adults remain underexplored. Purpose This study aimed to: 1) assess the association between ceramide scores and CVH and atherosclerotic CVD (ASCVD) risk among African American adults and 2) compare ceramide scores between African American and White adults. Methods Health surveys and ceramides measurements were conducted for African American and White adults, both recruited from population-based observational study cohorts. Ten-year pooled cohort risk ASCVD scores were calculated based on American College of Cardiology guidelines. CVH was assessed using Life’s Essential 8 (LE8) scores, as per American Heart Association rubrics. CV risk factors in the two cohorts were compared using Chi-squared tests. Linear regression and Pearson correlation assessed the association between ceramide, LE8, and ASCVD risk scores. Linear regression, adjusted for age and sex, compared ASCVD risk and ceramide scores between the two cohorts. Results In total, 58 African American (mean age [SD] 54.5 [11.9] years, 67.9% women) and 1103 White (mean age [SD] 64.5 [11.9] years, 52.1% women) adults were included (Table 1). Compared to White adults, African American adults had a higher prevalence of overweight/obesity (92.9% vs 33.6%; p&lt;0.001), hypertension (69.6% vs 42.5%; p&lt;0.001), diabetes (30.4% vs 12.2%; p&lt;0.001), and hyperlipidaemia (42.9% vs 30.0%; p=0.03). No difference in mean ASCVD risk was observed between the African American (12.8% [SD 10.4]) and White (12.6% [SD 11.1]) cohorts (p= 0.91). African American adults had lower 18:0 (0.08 [0.03] vs 0.10 [0.04] μmol/L) and 24:1 (0.91 [0.31] vs 1.17 [0.33] μmol/L) ceramides compared to White adults (p&lt;0.001). Ceramide scores among African American adults were not associated with LE8 scores (p=0.077) or ASCVD risk scores (r=-0.12, p=0.428). Adjusting for age and sex, African American adults had lower ceramide scores compared to White adults (mean [SD] 1.90 [1.97] vs 3.48 [2.88], p=0.006). Conclusions In our study comparing African American and White adults in the community, the association observed between ceramide scores and CVH or ASCVD risk scores in the African American cohort did not reach statistical significance. Interestingly, despite a more suboptimal cardiometabolic profile, African American adults had lower ceramide scores compared to White adults. Our findings suggest that ceramide profiles may not accurately reflect cardiovascular risk in African American adults, warranting further exploration of alternative sphingolipid biomarkers of risk for this population.